Conclusions
The data provide evidence that the intra-thyroidal production of IL-14 and IL-16
is associated with the pathogenesis of autoimmune thyroid disease. Thyroid follicular cells display the ability to express IL-14 and IL-16 mRNA and can be stimulated to express protein, by a panel of cytokines, and IL-14 protein, by as yet unidentified factors. expressions of thyroid dysfunction due to autoimmunity. 1 HT is characterised by infiltration of thyroid-specific T lymphocytes and other immune cells, thyroid enlargement and fibrosis, and progressive destruction of thyrocytes, eventually resulting in hypothyroidism. 2 Patients with GD may show lymphocytic infiltration and some damage to the thyroid, but the disease is characterized by hyperthyroidism due to excessive production of thyroid hormone induced by specific autoantibodies against the thyrotropin receptor. 3 Although several factors, including genetic, hormonal, and environmental, have been implicated in the initiation and/or development of thyroid autoimmunity, 4 the changes associated with the pathophysiology of autoimmune thyroid disease are orchestrated by an array of cytokines. 5 Particularly, pro-inflammatory Th1-and Th17-specific cytokines, which can be produced by thyroid follicular cells as well as thyroid-infiltrating T lymphocytes, have a role in promoting thyroid autoimmunity. [6] [7] [8] [9] Interleukin (IL)-14 is produced mainly by T lymphocytes and acts to stimulate B cell proliferation, expand selected B cell subgroups, and inhibit antibody secretion. 10 It has been implicated in the pathogenesis of autoimmune diseases, systemic lupus erythematosus and Sjögren's syndrome. 11, 12 Given the importance of the humoral immune response in autoimmune thyroid disease, particularly GD, IL-14 may be directly involved in initiation and/or progression of the autoimmune process. In contrast, IL-16 is involved in cellular immune responses 13, 14 and is produced by several cell types including epithelial cells, fibroblasts, monocytes, lymphocytes and eosinophils. [15] [16] [17] [18] This cytokine plays a role in a number of auto-inflammatory conditions, including rheumatoid arthritis, Crohn's disease Given the potential for involvement of IL-14 and IL-16 in autoimmune thyroid disease pathogenesis, the aim of the current study was to analyse the expression of IL-14 and IL-16 in the thyroid tissue of patients with either GD, HT or multi-nodular goitre (MNG) and in that of normal individuals, in intra-thyroidal CD4 + and CD8 + T cells derived from GD and HT patients, and in primary thyrocytes taken from diseased and normal thyroids, as well as in the human thyroid cell line HT-ori3. Overall, this study will aim to establish the role of IL-14
and IL-16 in autoimmune thyroid disease which is an important step to fully understand disease pathogenesis and uncover potential future therapeutic targets. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w 6
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Materials and methods
Patients and thyroid tissue samples
Local ethical committee approval was obtained for the study and informed written consent was obtained from all participants prior to inclusion in the study. Disease diagnosis was confirmed in all GD (n = 9), HT (n = 4) and non-toxic, non-autoimmune MNG (n = 13) patients by biochemical testing and histological examination. All HT patients had high antibody titres against thyroid peroxidase, whereas seven out of nine GD patients had raised anti-thyroid peroxidase antibody titres, with data unavailable for the remaining two. All patients with HT and GD had been treated with thyroxine and carbimazole, respectively, prior to surgery.
Surgery in the HT patients was performed either for diagnostic purposes, because lymphoma was suspected (but not subsequently confirmed) or to remove a painful or a cosmetically disfiguring goitre. Patient thyroidectomy specimens were either snap-frozen in liquid nitrogen or processed to obtain either thyroid-infiltrating immune cells or thyroid follicular cells. Snap-frozen thyroid tissue samples were also obtained from six normal individuals (ProteoGenex, Culver City, CA, USA).
Isolation of intra-thyroidal CD4 + and CD + T cells
Intra-thyroidal lymphocytes were prepared from GD and HT patient thyroidectomy specimens by collagenase/Dispase digestion as described previously. 24 CD4 + and CD8 + T cells were isolated using magnetic Dynabeads ® M-450 beads (Dynal Biotech, Oslo, Norway), according to the manufacturer's protocol. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w 7
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Thyroid follicular cells
The human thyroid cell line HT-ori3 was established by transfection of normal human thyrocytes with a plasmid-borne origin-defective SV40 genome, as previously described.
25
Thyroid follicular cells were prepared from GD patient thyroidectomy specimens using methods described elsewhere. 26 Promega, Southampton, UK) was used to synthesise cDNA, as previously described.
27
Oligonucleotide primers (Life Technologies Ltd.) for PCR amplification of cDNA samples were designed according to previously published DNA sequences of IL-14 10 and IL-16. 13 The primer sequences were 5'-CAGCTCATACTGCTCATTCA-3' (forward) and 5'-TCCTACAGAAAAAGCAGAGC-3' (reverse) for IL-14, and 5'-ATTCACTCATACATCTGGCC-3'
(forward) and 5'-TGCTTCACCTGTACTCCTCT-3' (reverse) for IL-16. The primer sequences for β−actin have been described previously. 27 PCR amplification reactions were performed as detailed earlier, 6 with 27-29, 30-32 and 22-24 cycles used for IL-14, IL-16 and β-actin amplification, respectively. Control PCR amplifications without cDNA were carried out in parallel and were consistently negative. PCR amplification products were separated in 1%
(w/v) agarose gels and their identification confirmed by Southern blotting and hybridisation using internal oligonucleotide probes (Life Technologies Ltd.), as previously described. were collected prior to treatment at 0 h and at the stated time points, centrifuged at 500 g for 10 min, and then analysed for IL-14 and IL-16 protein levels in IL-14-or IL-16-specific ELISAs, respectively. After 24 h, untreated and treated thyrocytes were collected for the preparation of protein extracts, as detailed above.
Cytokine ELISAs
IL-14-and IL-16-specific ELISAs were used according to the manufacturers' protocols. The IL-14 ELISA (Cloud-Clone Corp, Houston, TX, USA) had an assay range of 15.6-1000 pg/ml, a sensitivity of < 5.6 pg/ml, and intra-and inter-assay coefficients of variation of < 10%. The IL-16 ELISA (Thermo Scientific, Inc., Rockford, IL, USA) had an assay range of 0-2000 pg/ml, a 
Results
IL-14 and IL-16 mRNA and protein expression in thyroid tissue samples
The expression of IL-14 and IL-16 mRNA was analysed in thyroid tissue using RT-PCR amplification. IL-14 mRNA expression was detected in thyroid tissue from 8/9 GD, 3/4 HT and 3/13 MNG patients, as well as 1/6 normal individuals (Fig. 1a) . IL-16 mRNA was found in thyroid tissue from 9/9 GD, 4/4 HT and 9/13 MNG patients, in addition to 4/6 normal individuals (Fig. 1a) .
The expression of IL-14 and IL-16 protein was analysed in thyroid tissue extracts using western blotting. IL-14 protein was detected as a 70-kD band in thyroid tissue extracts derived from 6/6 GD and 1/1 HT patients, but not in any samples taken from six MNG patients or six normal individuals (Fig. 2a) . This was greater than the expected molecular weight of 60-62 kD.
28 IL-16 protein was identified at 68 kD in thyroid tissue extracts from 6/6 GD, 1/1 HT and 1/6 MNG patients, but was not found in any of six normal individuals (Fig.   2a ). The protein detected by western blotting was assumed to represent the precursor form of IL-16, pro-IL-16, which has a molecular weight estimated from its cDNA sequence of 69 kD, in comparison to the secreted 14-kDa active C-terminal part of the cytokine.
29
IL-14 and IL-16 mRNA expression in intra-thyroidal CD4 + and CD8 + T cells
As the thyroids of patients with autoimmune thyroid disease are infiltrated with T lymphocytes which could be a source of IL-14 and IL-16 in the tissue, the expression of mRNA for both cytokines was analysed by RT-PCR amplification in intra-thyroidal CD4 + and CD8 + T cells derived from two GD and two HT patients. IL-14 mRNA was detected in both intra-thyroidal CD4 + and CD8 + T cells from all four patients (Fig. 1b) . In contrast, IL-16 mRNA (Fig. 1b) and in none of the samples taken from the two GD patients.
IL-14 and IL-16 mRNA and protein expression in thyroid follicular cells
To investigate whether thyroid follicular cells could be a source of IL-14 and IL-16 in the thyroids of autoimmune disease patients, the expression of both cytokines in terms of mRNA and protein was analysed. IL-14 and IL-16 mRNA expression was detected by RT-PCR amplification in cultured HT-ori3 cells and in thyroid follicular cells derived from two patients with GD and one normal individual (Fig. 1c) .
By western blotting, IL-14 and IL-16 proteins were not detectable in extracts of cultured HT-ori3 cells or cultured thyroid follicular cells derived from two patients with GD and from one normal individual (Fig. 2b) . In contrast, both IL-14 and IL-16 proteins were evident in extracts of all thyrocyte cultures following treatment with PBMC-conditioned medium (Fig. 2b) .
Effect of cytokine and TSH treatment on IL-14 and IL-16 protein expression by cultured thyrocytes
To analyse the potential for cytokines and TSH to affect the expression of IL-14 and IL-16
protein by thyrocytes, cultured HT-ori3 cells and thyroid follicular cells derived from two patients with GD and from one normal individual, were treated with IL-1β, IL-1α, IL-17A, IL-4, TGF-β, TNF-α, IFN-γ, PBMC-conditioned medium and TSH. IL-14-and IL-16-specific ELISAs were used subsequently to detect the levels of IL-14 and IL-16 protein expressed and secreted into the culture medium by untreated and treated cultured thyrocytes. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 13 The results showed that PMBC-conditioned medium induced IL-14 protein expression, which was detected after 6 h of stimulation, by HT-ori3 cells, thyrocytes from GD patients, and thyroid follicular cells from a normal individual (Fig. 3a-c) . IL-14 protein expression was not detectable by HT-ori3 cells, thyroid follicular cells from GD patients or thyrocytes from a normal individual (Fig. 3a-c) even after treatment for 24 h with IL-1α, IFN-γ, TSH or TNF-α.
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Likewise, TGF-β, IL-1β, IL-4 and IL-17A were not stimulatory factors for IL-14 protein expression by HT-ori3 cells (Fig. 3a) or by thyrocytes from a normal individual (Fig. 3c) .
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